Albireo is an independent Swedish biotechnology company, which brings unique translational approaches to develop drugs that fulfil unmet medical needs in the gastrointestinal (GI) area. The team has a broad experience in drug development, primarily in the GI area and has an extensive network in the international scientific and clinical communities.
Albireo was spun-out of AstraZeneca in February 2008. Albireo is financed by a syndicate of growth capital firms, led by Nomura Phase4 Ventures and supported by other specialist investors in the healthcare markets including TVM Capital and Scottish Widows Investment Partnership. The company has raised $40m in a Series A financing round. The company is focused on developing novel therapies that address unmet medical needs in the GI area. Specifically, we are concentrating on generating significant clinical data for our lead programme in chronic constipation, and on progressing our pre-clinical assets into the clinic. We will achieve this by: Exploiting our expertise and experience in translational research, Drawing on our extensive knowledge and track record in drug development,Leveraging our extensive network in the scientific, clinical, academic and pharma communities, and Managing all our internal and external capabilities in a cost effective way
We believe that people and relationships ultimately determine success. We are committed to achieving excellence in everything we do, delivering distinctive projects to successful fruition. We make every effort to identify, attract and develop the best talent for our business. We devote the same energy to our partners, creating long-term, mutually beneficial relationships, focused on delivery.
We encourage individual creativity but believe that team effort often produces the best results. We promote opportunities to contribute, providing a positive environment of curiosity and development. In the rapidly changing world of biotech and pharmaceuticals we work to constantly anticipate changes and develop innovative approaches to meeting our goals.
We value diversity and strive to provide an exciting and inclusive environment, treating all stakeholders as we would like to be treated ourselves. We seek to inspire trust and respect by taking responsibility for our actions, maintaining high ethical standards and encouraging honest and open dialogue with all those who have an interest in our business.
A3309 is a therapeutic alternative with a novel mechanism of action developed for the treatment of CIC and IBS-C. A3309, which has minimal systemic exposure, modulates the re-uptake of bile acids by inhibiting the ileal bile acid transporter (IBAT or ASBT). This results in an increased concentration of bile acids in the colon which, in turn, increase fluid secretion and colonic motility. These physiological responses should provide benefits to patients with CIC and IBS-C without any effects on other parts of the gastrointestinal tract.
Albireo is a unique and exciting investment opportunity. The high quality programmes led by a management team with extensive experience in scientific and clinical development in the GI field, as well as extensive links to industry and academia, enabled Albireo to raise $40m in a Series A financing round from leading healthcare investors.
Phase4 Ventures is a leading venture capital firm based in London that invests in development stage life science companies in the US and Europe. Founded in 1999, the team has made more than 30 investments in mid-to-late stage life science companies. Phase4 Ventures was spun-out from Nomura in December 2010 following a buy out of the management company by the team and a secondary purchase of a fund by Harbourvest Partners. Phase4 currently manages funds for both Nomura and Harbourvest.
TPGBiotech was founded in 2001 and has over $700M of capital under management anda team of experts in healthcare to catalyze the creation of newbusinesses. We invest in five main areas - drug discovery anddevelopment, personalized diagnostics, pharmaceutical outsourcing businesses,industrial biotechnology and medical devices. We invest across the full spectrumof company stage, from making seed investments and starting companies toinvesting in public companies. We aim to invest $25-30MM in each company overthe lifetime of our investment.
TVM Capital funds have made investments in more than 235 technology and life science companies. Over the life of the firm, TVM Capital has developed specialized, focused teams and dedicated funds to serve high-growth target markets. The TVM Capital investment strategy is to create global businesses that enjoy worldwide access to science, technology, management talent and capital, and to develop them into significant players in their markets.
Scottish Widows Investment Partnership (SWIP) is one of Europe`s largest asset management companies and part of the Lloyds TSB Group. SWIP managed funds worth £97.6bn (as at 31 December 2007), which are invested in all major asset classes, including domestic and overseas equities, property, bonds and cash. Under its own name and in partnership with overseas-based organisations, SWIP has a physical presence that stretches around the world